2012 NOV 26 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Cannabis Science, Inc., (CBIS) announces Harvard Medical School releases peer-reviewed study in the Genes & Cancer Journal strongly suggesting that Cannabidiol inhibits growth and induces programmed cell death in Kaposi Sarcoma-associated Herpesvirus-Infected Endothelium. These results from the study at Harvard Medical School support Cannabis Science's approach to the development of CS-TATI-1 to inhibit Kaposi Sarcoma (see also Cannabis Science, Inc.).
Cannabis Science President & CEO, Dr. Robert Melamede states, "We are very encouraged to see the publication of the Harvard study that demonstrates the ability of phytocannabinoids to inhibit Kaposi cells. The Harvard results confirm and emphasize the direction that we have been developing with our initial drug CS-TATI-1 to inhibit Kaposi Sarcoma. Cannabis Science is in the process of submitting several concept sheets to publicly sponsored research programs to move CS-TATI-1 into the clinic as rapidly as possible to the satisfaction of regulatory review for commercialization."
David Purdy, CEO & Founder, World AIDS Institute comments, "This groundbreaking Harvard study on the investigation of the effects on KS by cannabinoids is a fundamental game changer in the treatment of a disease that is one of the top causes of AIDS-related deaths in the world. In fact, there has been a precipitous drop in interest in KS treatment research in the activist world despite the devastation on the African continent caused by this particular AIDS-related malady."
Keywords for this news article include: Genetics, HIV/AIDS, Kaposi Sarcoma, Cannabis Science Inc., Opportunistic Infections.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC